Suriclone, with the CAS number 53813-83-5, is a chemical compound primarily recognized for its use as a sedative and anxiolytic agent. It belongs to the class of compounds known as benzodiazepines, which are characterized by their ability to enhance the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor. This action results in a calming effect on the central nervous system, making Suriclone effective in treating anxiety and sleep disorders. The compound typically exhibits a rapid onset of action and a relatively short duration of effects, which can be beneficial in clinical settings. However, like other benzodiazepines, it may lead to dependence and withdrawal symptoms if used long-term. Additionally, potential side effects can include drowsiness, dizziness, and impaired coordination. As with any medication, it is essential to use Suriclone under medical supervision to mitigate risks and ensure appropriate therapeutic outcomes.

Suriclone

53813-83-5: Suriclone, 1-Piperazinecarboxylic acid, 4-methyl-, 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxo-5H-1,4-dithiino[2,3-c]pyrrol-5-yl ester, Suril, 5H-1,4-Dithiino[2,3-c]pyrrole, 1-piperazinecarboxylic acid deriv., RP 31264

Suriclone (RP 31264), a cyclic pyrrolidone for anxiety, modulates GABA-A receptors without major sedation.

CAS 53813-83-5: Suriclone

Suriclone

Ref: TM-T28887

Suriclone

Ref: 54-BUP00932